NVO Novo Nordisk A/S

-0.12  -0%
Previous Close 48.51
Open 48.59
Price To Book 14.75
Market Cap 115458581277
Shares 2,386,000,853
Volume 1,127,664
Short Ratio 2.81
Av. Daily Volume 1,273,992

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

NDA filing announced March 20, 2019. Estimated PDUFA date September 20, 2019 assuming 6-month priority review.
Semaglutide - oral - PIONEER
Type 2 diabetes
Phase 3 trial to be initiated 3Q 2019.
Concizumab - explorer
Hemophilia A
Approval announced August 25, 2017.
Victoza (liraglutide)
Type 2 diabetes
Approved September 29, 2017.
Fiasp (fast-acting insulin aspart)
Type 1 and type 2 diabetes
Phase 3 trial to be initiated 2Q 2019.
Growth Hormone Deficiency (GHD)
Phase 2 data due 2Q 2019.
Anti-IL 21 GLP-1 T1D (NNc)
Type 1 diabetes
Approval announced December 5, 2017.
Type 2 diabetes
Approval announced May 31, 2017.
Nonacog beta pegol
haemophilia B
FDA Approval announced February 19, 2019.
Hemophilia A
Phase 2 data due 4Q 2019.
Type 2 diabetes
Phase 2 trial to commence 1Q 2019.

Latest News

  1. Novo Nordisk's (NVO) Share Price Rises YTD on Strong Pipeline
  2. Gilead Collaborates With Insitro to Develop NASH Therapies
  3. Biotech Stock Roundup: GILD Collaborates on NASH, FCSC Surges on Deal
  4. Gilead to Collaborate with Novo Nordisk for NASH Treatment
  5. Gilead Sciences Teams With Novo Nordisk for Trials of Liver Disease Drugs
  6. Novo Nordisk and Gilead team up to test fatty liver disease treatment
  7. Why Fundamental Investors Might Love Novo Nordisk A/S (CPH:NOVO B)
  8. Sangamo Rises on Positive Phase I/II Hemophilia Study Data
  9. Here is What Hedge Funds Think About Adobe Inc. (ADBE)
  10. Insurance Companies Benefit the Most From Rising Insulin Prices
  11. Novo Nordisk A/S (NVO): Hedge Funds Are Snapping Up
  12. Bull of the Day: DexCom (DXCM)
  13. Novo Nordisk A/S (CPH:NOVO B): Ex-Dividend Is In 4 Days
  14. REVIEWAPALOOZA!: 5-Stock Samplers
  15. Lilly to Bring Half-Priced Version of Popular Humalog Insulin
  16. What's in the Cards for Aeterna (AEZS) This Earnings Season?
  17. Novo Nordisk files for a label update for Fiasp® to the EMA and the FDA seeking approval for use in children and adolescents
  18. Ophthotech's (OPHT) Q4 Loss Wider, Gene Therapy in Focus
  19. Strongbridge Biopharma plc (SBBP) Q4 2018 Earnings Conference Call Transcript
  20. Pharma Stock Roundup: MRK Buys IMDZ, FDA Grants Priority Review to Some Candidates